… Drug Administration (FDA) grants Priority Review to applications for medicines … “The DESTINY-Breast09 trial showed that treating … docetaxel or paclitaxel], trastuzumab and pertuzumab) as a 1st-line treatment … or DESTINY-Lung05 trials. Continued approval in …

… study or discontinued the trial. “We anticipate results … 50%) patients who received docetaxel in the castrative-sensitive … have significantly higher on-treatment frequency of circulating effector … an immune-modulating antibody-drug conjugate targeting CD46, in …

… made its mark with FDA approved Ga-68 … to existing treatments such as chemotherapy drugs like docetaxel (for … trial enrollment reflects strong belief in this science from doctors … and next-generation radiopharmaceutical trials, he offers perspective that …

… treatment, or management options for a specific patient’s medical … . More recently, an antibody-drug conjugate (ADC) targeting c … , as determined by an FDA-approved test; additional criteria … NSCLC-01 trial is comparing telisotuzumab vedotin with docetaxel as …

… resists conventional treatments. Microcatheter-assisted drug-loaded microspheres … ); (2) Docetaxel, released from drug-loaded microspheres, inhibits … collaboration across clinical medicine, data science, … doi:10.3390/pharmaceutics14020359. 10. Nicoletti R …

… cancer treatment. The study, conducted by a team of experts in pharmaceutical … effects and suboptimal distribution of medications to cancer cells. This … : Nanoparticles, extracellular vesicles, docetaxel, cancer therapy, drug delivery systems. Tags: advances …

… intravesical system, a fourth treatment has become available, offering … of intravesical—that’s medication put inside the bladder— … . We’ve got 3 drugs, all with different mechanisms … from intravascular gemcitabine/docetaxel. U.S. FDA approval of INLEXZO™ …

… -Presbyterian – Weill Cornell Medical Center, discussed factors to … (Pluvicto) and docetaxel for the treatment of patients with … In March 2025, the FDA expanded the indication for … in these scenarios, tailoring treatment based on patient characteristics …

… 18 months in clinical trials.2,3 Despite this … -DXd), an antibody-drug conjugate linking trastuzumab to … treatment and any medical condition deemed to compromise patient safety or trial … Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast …

… , advanced treatment platforms are achieving complete tumor elimination in clinical trials across … Biotech Inc. , Anixa Biosciences, Inc. , IceCure Medical Ltd. , ImmunityBio, Inc. , and Regeneron Pharmaceuticals …